A seismic shift is underway for inflammatory bowel disease therapies as a trio of newly approved interleukin-23 inhibitors are poised to challenge both the resident blockbuster and an avalanche of its …
‘More options’ flood IBD market as rival IL-23 drugs face off with Stelara biosimilar boom
view original post